



The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

**16 November 2017**

**Tekcapital plc  
("Tekcapital" or the "Company")**

**Update re. Belluscura IPO**

The Board of Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property investment services, is delighted to note the Schedule One announcement (the "Schedule One Announcement") and the Intention to Float announcement (the "Intention to Float Announcement") released today on behalf of Belluscura Limited ("Belluscura"), in connection with the proposed admission of Belluscura's ordinary shares to trading on AIM in conjunction with a placing of new ordinary shares to raise funds (the "Belluscura IPO").

The Schedule One Announcement states that the admission of Belluscura's ordinary shares to trading on AIM ("Admission") is expected to take place in December 2017. The Intention to Float Announcement indicates that Belluscura is seeking to raise £7.5 million to £10 million in the placing. Belluscura's anticipated market capitalisation on Admission is yet to be confirmed. Tekcapital currently owns 47.5% in Belluscura, which at 31 May 2017 had a carrying value in Tekcapital's unaudited balance sheet of US\$3,676,123. Although Tekcapital's stake in Belluscura will be diluted by the Belluscura IPO, Tekcapital anticipates the value of its stake may increase as a result.

The Intention to Float Announcement notes that Belluscura has recently entered into a conditional agreement to acquire from Stryker Corporation the licenses to manufacture and sell the STIC™, a hand held pressure monitor for the measurement of compartment pressure, a standard of care product line which generated average annual sales of approximately \$4 million between 2011 and 2016.

As noted in previous Tekcapital announcements, Belluscura has previously acquired licenses to manufacture and sell four medical device product lines from Stryker, a Fortune 500 New York Stock Exchange listed medical technology company, namely the SNAPII™, the Passport®, the Slyde™ and the Wire Caddy™. Belluscura has also previously entered into a co-exclusive license and development agreement with Separation Design Group LLC to complete the development of CURV™, a portable oxygen concentrator, used to deliver concentrated oxygen to a patient requiring oxygen therapy.

It is anticipated that a restructuring of Belluscura's board of directors will take place in connection with the Belluscura IPO. Harry Hyman will become Belluscura's Non-Executive Chairman and Anthony Francis Martin will be Non-Executive Director. Robert Rauker and Michael Van Hoy will continue to perform the roles of Chief Executive Officer and Chief Technical Officer respectively and have been joined by Anthony Dyer, who will perform the role of Chief Financial Officer.

Tekcapital will make further announcements in respect of the Belluscura IPO process in due course.

**For further information, please contact:**

**Tekcapital Plc**

Clifford M. Gross, Ph.D.

[info@tekcapital.com](mailto:info@tekcapital.com)

**Allenby Capital Limited (AIM Nominated  
Adviser & Joint Broker)**

Jeremy Porter / Alex Brearley

**+44 (0) 20 3328 5656**

**Dowgate Capital Stockbrokers (Joint Broker)**

David Poutney / James Serjeant

**+44 (0) 1293 517744**

**Walbrook PR Ltd**

Paul Cornelius / Helen Cresswell / Sam Allen

**+44 (0) 20 7933 8780**

[tekcapital@walbrookpr.com](mailto:tekcapital@walbrookpr.com)

**Tekcapital plc - *The World's Largest University Network for Open Innovation***

Tekcapital's objective is to create value from investing in new, university-developed intellectual properties and produce returns through capital appreciation. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital makes it easy to find and acquire the new IP needed to create a competitive advantage. Our IP services include invention discovery reports, search tools, analytics and IP professional recruitment to help universities and companies create value from new discoveries. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit [www.tekcapital.com](http://www.tekcapital.com)

**LEI: 213800GOJTOV19FIFZ85**